Read Time:
Cobra Biologics, the gene therapy division of the Cognate BioServicesâ group, has today announced a multi-phase augmentation of its plasmid DNA services as a continuation of its Gene Therapy servicesâ expansion project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ (High Quality) DNA manufacturing capacity alongside new clinical and commercial GMP DNA facilities at its European facilities. The HQ plasmid manufacturing service provides a rapid six-week delivery time for the clinical manufacture of immuno-oncology therapies, for example products utilizing AAV, lentiviral vector and CRISPR products.
After its acquisition of Cobra Biologics in January 2020, Cognate has positioned itself as a global provider of end-to-end capabilities in the development and manufacturing of cell & gene therapy products. This expansion is in direct response to the great demand of commercial capacity within the biologics industry.
Cognate BioServices Announces Major Expansion of Manufacturing Facilities in US and Europe
News provided by
Share this article
Share this article
MEMPHIS, Tenn., Jan. 14, 2021 /PRNewswire/ Cognate BioServices, Inc., the premier commercial-ready, global CDMO in the Cell and Gene Therapy industry, announced today its plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and increase office support at its facilities in the United States and Europe.
Cognate BioServices is the leading provider of development & manufacturing support to the cell & gene therapy industry.
The expansion activities will nearly double the capacity at Cognate s existing Global Manufacturing Facility & Headquarters, located only minutes from Memphis International Airport, the world s second busiest cargo airport. In Memphis, Cognate will add two separate facilities – a distribution center to help manage global supply chain needs, and a third site focus